ProKidney Corp. (PROK) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ProKidney Corp. (PROK) closed at USD 1.47 on 2026-10-14, a change of -51.6 % over the past year, with a market capitalization of USD 580.81M.

ProKidney Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ProKidney Corp. key figures

Previous close

USD 1.47 (2026-10-14)

1-year change

-51.6 %

Market cap

USD 580.81M

Enterprise value

USD 1.23B

P/E ratio (trailing)

-2.65

P/E ratio (forward)

-2.48

EPS (trailing)

-0.55

EPS (forward)

-0.59

PEG ratio

n/a

Price to book

-0.34

Revenue growth

-32.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.27

Employees

231

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ProKidney Corp. and compare it with other stocks.